Revolution Medicines, Inc. (RVMD) is a precision oncology company developing targeted therapies for RAS-addicted cancers. The central target used here reflects 14 current analyst price targets rather than a single published consensus figure. Averaging these gives roughly $264.6, rounded to $265, with an approximate low-to-high range of $240 to $320. Independent aggregators point in a similar direction: a widely cited S&P Global poll of 25 analysts showed an average target near $258.84 and a "Strong Buy" rating, while TipRanks data placed the average near $257.
Bullish targets cluster in the $250s to $270s, with the highest marks from Evercore ISI ($320) and Brookline ($318). More cautious views sit near $240–$250, and one notable low outlier around $82 in some aggregator data suggests at least one analyst still prices in meaningful downside or discounted pipeline scenarios. Recent actions lean constructive: RBC Capital lifted its target to $260, Truist to $241, and Morgan Stanley initiated coverage with an Overweight rating, while BofA trimmed its target modestly to $264. The wide range signals that the outcome depends heavily on clinical data and commercial execution rather than near-term earnings.
The stock recently traded near $191.31, well off its 52-week high of roughly $224 and far above its 52-week low near $57. Reaching $265 would require an advance of about 38.5%, which qualifies as a substantial move for an already high-multiple, cash-burning biotech. The path would most likely run through continued positive data and commercial uptake for daraxonrasib, expanded readouts across the broader RAS portfolio, and a re-rating of forward revenue expectations. Analysts' next-year revenue estimates jump sharply (to roughly $1.26 billion from around $200 million), underscoring how much of the valuation rests on launches and label expansions rather than current results.
The bull case centers on the RAS(ON) platform. Daraxonrasib (RMC-6236) has generated strong survival data in pancreatic ductal adenocarcinoma, and the company has progressed toward commercial-stage status following an approval, a milestone that prompted a wave of higher targets. Additional programs such as zoldonrasib and elironrasib extend the story into KRAS G12C and other RAS-mutant lung cancers, giving analysts multiple shots on goal. The consensus rating is overwhelmingly positive, and the steady upward revision of targets through 2026 reflects growing confidence in the franchise's revenue potential.
The risks are equally material. Revolution Medicines is unprofitable, with widening GAAP net losses (a $644 million quarterly loss in mid-2026) as it funds a large, expensive pipeline. Its valuation is stretched by traditional measures, and any clinical setback, regulatory delay, or slower-than-expected launch would pressure the stock. Competition in KRAS and RAS-targeted oncology is intensifying, and notable insider selling adds a layer of caution. Because the low end of the analyst range ($240) sits above but not far from the current price, the dispersion shows that even bulls disagree on how much future success is already reflected in the share price.
Technically, RVMD pulled back from its August peak near $224, a clear resistance zone that must be reclaimed before any move toward $265 becomes plausible. The $186–$192 area has acted as recent support, and a break below that zone could open the door toward lower levels. Above the 52-week high, the next durable reference points are psychological and prior-valuation milestones in the $240–$250 range. The long-term trend remains sharply higher over the trailing year, but the recent decline highlights sensitivity to news flow.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms differ. The nearest catalyst is the third-quarter 2026 earnings report and update, followed by clinical data readouts across the RAS portfolio, launch metrics for the approved program, and any FDA (U.S. Food and Drug Administration) or regulatory decisions on label expansions. Revisions to revenue and EPS (earnings per share) estimates, plus changes in analyst targets after data events, will be the clearest signal of whether the $265 objective moves closer or further away.
For traders seeking a systematic complement to fundamental research, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. This can help investors discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening. Traders interested in an AI-assisted view of names like RVMD may find these signals a useful addition to their workflow.
The $265 target for Revolution Medicines is a calculated average of 14 current analyst price targets, not a guarantee, and it sits about 38.5% above the latest price — a substantial move that hinges on continued pipeline success and commercial execution. The bull case is anchored in a differentiated RAS-targeted oncology franchise with strong pancreatic cancer data, while the bear case points to persistent losses, a rich valuation, competition, and a wide $240–$320 target range that reflects real disagreement. Investors should watch the quarterly update, clinical readouts, launch metrics, and analyst revisions before drawing conclusions about whether $265 is attainable.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, RVMD has been loosely correlated with GLUE. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if RVMD jumps, then GLUE could also see price increases.
| Ticker / NAME | Correlation To RVMD | 1D Price Change % | ||
|---|---|---|---|---|
| RVMD | 100% | +3.22% | ||
| GLUE - RVMD | 44% Loosely correlated | -2.07% | ||
| SYRE - RVMD | 39% Loosely correlated | +3.94% | ||
| ARRY - RVMD | 39% Loosely correlated | +22.11% | ||
| AXON - RVMD | 39% Loosely correlated | -2.08% | ||
| REPL - RVMD | 38% Loosely correlated | +5.95% | ||
More | ||||